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Riassunto 
 
Il danno al DNA e la perossidazione lipidica delle membrane cellulari 
sono le principali e più studiate conseguenze dello stress ossidativo. I 
meccanismi alla base di questi processi deleteri sono in gran parte 
noti, e vi sono evidenze crescenti che essi possano essere modulati sia 
da un corretto stile di vita, inclusa l’alimentazione, che da modifiche 
post-traduzionali di proteine, come la poli(ADP-ribosil)azione.  
La reazione di poli(ADP-ribosil)azione, catalizzata dalle poli(ADP-
ribosio) polimerasi, e coinvolta in numerosi processi cellulari, è 
considerata tra le modifiche post-traduzionali con caratteristiche 
epigenetiche. Le poli(ADP-ribosio) polimerasi nucleari 1 e 2 sono 
attivate da tagli al DNA. L’iperattivazione si traduce in 
automodificazione delle stesse con lunghi polimeri di ADP-ribosio, 
che contribuiscono a reclutare il macchinario di riparazione dell’acido 
nucleico. Quanto più il danno al DNA è esteso, tanto maggiore sarà il 
livello di automodificazione delle poli(ADP-ribosio) polimerasi. 
D'altra parte, i lipidi derivati dall’alimentazione vengono incorporati 
nelle membrane cellulari, possono essere molecole di segnalazione, 
dare origine a composti pro-infiammatori (ω6) ed anti-infiammatori 
(ω3), ed, in quanto costituenti delle membrane cellulari, sono buoni 
marcatori del loro squilibrio. 
In questo lavoro di tesi sono riportati i risultati di uno studio condotto 
al fine di stabilire se la combinazione delle due diverse analisi, cioè la 
determinazione dei livelli di poli(ADP-ribosio) polimerasi modificata 
e l’analisi della composizione fosfolipidica della membrana 
eritrocitaria, possano rappresentare un valido strumento per valutare lo 
stato fisio-patologico della cellula, e correlarlo con lo stile di vita, la 
dieta o gli stati patologici.  
Le due analisi sono state condotte, in doppio cieco, su 95 individui 
sottoposti ad endoscopia. I soggetti sono stati intervistati per 
raccogliere i dati anamnestici e clinici, se presenti. I linfociti e gli 
eritrociti sono stati preparati da sangue venoso per analizzare, 
rispettivamente, l’automodificazione della poli(ADP-ribosio) 
polimerasi e il contenuto dei fosfolipidi di membrana. I risultati sono 
stati poi valutati statisticamente.  
La determinazione dell’automodificazione della poli(ADP-ribosio) 
polimerasi ha confermato che, per quelle patologie che si 
  
 
accompagnano a livelli differenti di danno al DNA, 
l’automodificazione delle PARP correla con l’entità del danno, e 
rappresenta uno strumento per valutare lo stato clinico della malattia, 
in funzione del trattamento chirurgico/terapeutico applicato.  
Dal profilo lipidico della membrana eritrocitaria dei vari soggetti, è 
emerso il livello di squilibrio dei lipidi, correlabile sia ad 
alimentazione/stile di vita che a stati infiammatori associati a 
patologie. Nella maggior parte dei casi presi in esame ciascuna delle 
analisi ha dimostrato di fornire, separatamente, informazioni sulle 
condizioni fisio-patologiche dei soggetti, e di ottenere indicazioni sia 
sullo squilibrio di membrana che di alterata funzionalità di specifiche 
vie del metabolismo del DNA e/o dei lipidi; in alcuni casi è risultata 
evidente una correlazione di entrambe le analisi, con  specifiche 
patologie. Ciò suggerisce che la combinazione dei due test nella 
routine di laboratorio, potrebbe mettere in evidenza alterazioni a 
livello del nucleo e delle membrane, preliminari ad una diagnosi di 
una specifica patologia ottenibile poi dal quadro clinico.  
Da questo lavoro è emerso che l’automodificazione della PARP e il 
profilo lipidomico della membrana definiscono possibili biomarcatori 
per un monitoraggio sensibile, non invasivo e di routine dello stato 
fisio-patologico delle cellule. 
  
 
Summary 
 
Membrane lipid peroxidation and DNA damage are the main and most 
studied consequences of free radicals. The mechanisms underlying 
these deleterious processes are mostly known and there are increasing 
evidence that they might be modulated by a correct quality of food 
intake and post-translational modification reactions (namely 
poly(ADP-ribosyl)ation), respectively. 
Poly(ADP-ribosyl)ation, catalysed by poly(ADP-ribose) polymerases, 
affects many cellular events and has a recognized epigenetic role. 
Nuclear poly(ADP-ribose) polymerases 1 and 2 are hyperactivated by 
DNA strand breaks. They auto-modify with large polymers of ADP-
ribose and recruit DNA repair proteins. The more the DNA strand 
breaks, the more poly(ADP-ribose) polymerase modifies itself. 
On the other hand, dietary lipids can be signaling molecules, lead to 
pro-(ω6)/anti-(ω3) inflammatory compounds, and be included in 
biomembranes, good biomarkers of their unbalance. 
Here, we report the results obtained from a study to establish whether 
the combination of two different analyses, i.e. detecting auto-modified 
poly(ADP-ribose) polymerase levels and analyzing erythrocyte 
membrane fatty acid composition, might help to monitor the physio-
pathological state of the cell, and to correlate with lifestyle, diet or 
diseases. The two analyses were carried blindly on 95 subjects 
undergoing endoscopy. They were first interviewed, to collect 
anamnesis and clinical data, if present. Lymphocytes and erythrocytes 
were prepared from venous blood to assay poly(ADP-ribose) 
polymerase automodification and membrane fatty acid content, 
respectively. The results were statistically evaluated. The measure of 
poly(ADP-ribose) polymerase automodification confirmed that its 
levels correlate with DNA damage extent, within the same pathology, 
and allowed to monitor the clinical activity of the disease, depending 
on ongoing surgical/therapeutic treatment. Membrane fat profile was 
able to evidence unbalance of lipids linked to both diet/lifestyle and 
inflammatory states leading to diseases. In most analysed cases, each 
test demonstrated to evidence, separately, specific features of the 
physio-pathological state of the subject, i.e. membrane lipid 
unbalance, altered function(s) of specific pathways of DNA and/or 
lipid metabolism. In other cases, a correlation between both analyses 
  
 
and specific pathologies emerged. This finding suggested that in the 
laboratory routine, combining the two tests might be a preliminary 
step to investigate the occurrence of a given disease, before 
confirming the diagnosis with other specific clinical analyses.  
Both PARP automodification and membrane lipidomic profile provide 
possible biomarkers for sensible, non-invasive and routine monitoring. 
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1. Introduction 
The epigenome is an essential mechanism for the regulation of the 
genome that depends on modifications of DNA and histones but does 
not involve any change of the DNA sequence (Jablonka & Raz, 2009). 
Epigenetic changes have been observed in response to environmental 
influence (Reik, 2007). Stress, diet, behaviour, exposure to toxicants, 
and other factors, activate chemical switches that regulate gene 
expression. Diet is one of the most studied environmental factors in 
epigenetic changes (Waterland & Jirtle, 2003). There are increasing 
evidence that a correct quality of food intake and post-translational 
modification reactions (namely poly(ADP-ribosyl)ation) might 
modulate deleterious processes as membrane lipid peroxidation and 
DNA damage respectively. 
 
1.1 Poly(ADP-ribosyl)ation and DNA damage response 
Poly(ADP-ribosyl)ation is a post-translational modification of proteins 
catalysed by poly(ADP-ribose) polymerases, PARPs. PARPs use β-
NAD
+ 
as a substrate to synthesize and transfer ADP-ribose (ADPR) 
units onto specific amino acid residues of target proteins (Hassa et al., 
2006).  
The acceptor proteins are covalently modified by ADP-ribose 
polymers (PAR) up to several hundred ADP-ribose residues with 
branching and large negative charges (Bai & Cantó, 2012). PAR can 
be rapidly degraded in vivo by poly(ADP-ribose) glycohydrolase 
(PARG), an enzyme that possesses both endo- and exoglycosidic 
activity and is the only protein known to catalyse the hydrolysis of 
ADP-ribose polymers to free ADPR, Figure 1 (Davidovic et al., 
2001). 
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Figure 1: Metabolism of poly(ADP-ribose).  
Poly(ADP-ribose) polymerase 1 (PARP1) hydrolyzes NAD
+
 to polymerize ADP-
ribose units on substrate proteins, with the concomitant release of nicotinamide. 
PARP1 catalyzes the three steps of poly(ADP-ribose) anabolism (red part of the 
cycle): (1) mono(ADP-ribosyl)ation of the acceptor protein substrate; (2) elongation; 
and (3) branching of the poly(ADP-ribose) chain. PARG (green side of the cycle) 
cleaves the glycosidic bonds between ADP-ribose units both at the ends and within 
the poly(ADP-ribose) chains, respectively; the cleavage sites are shown by dark 
green arrows (Rouleau et al., 2004). 
 
 
In the human genome 18 different genes have been identified that all 
encode PARP family members, Figure 2 (Amé et al., 2004). Not all 
PARP family members are enzymatically active, and some may 
function as mono(ADP-ribosyl) transferases rather than PARPs 
(Fabrizio et al., 2015; Grimaldi et al., 2015). As a consequence, 
Hottinger et al. (2010) proposed a new nomenclature describing 
PARPs more accurately as (ADP-ribosyl)transferases, ARTs, Figure 2 
(Ryu et al., 2015).  
 
 
Introduction 
3 
 
 
 
Figure 2: Functional domains of the human ARTD (PARP) family. 
The most relevant are: ART, is the catalytic core required for basal ART activity. 
PARP regulatory domain (PRD) might be involved in regulation of the PARP-
branching activity. WGR, characterized by the conserved central motif (W-G-R), is 
also found in a variety of a polyA polymerase and in protein of unknown function. 
BRCT domain (BRCA 1 carboxy-terminal domain) is found within many DNA 
damage repair and cell cycle checkpoint protein. Macro domain can serve as ADPR 
or 0-acetyl(ADP-ribose) binding module. ZF: zinc finger domains, recognizing 
DNA breaks (Hottinger et al., 2010).  
 
 
PARPs have key functions in a wide range of biological structures and 
processes (Li & Chen, 2014).  
The most representative enzymes of the PARP family are poly(ADP-
ribose) polymerase 1, PARP1 (113 kDa), the funding member, and 
poly(ADP-ribose) polymerase 2, PARP2, 62 kDa, Figure 3. Both are 
highly conserved proteins, ubiquitously expressed in mammalian 
tissues and with predominant nuclear localization (Bürkle, 2005). 
They are involved in several processes, as regulation of chromatin 
structure and transcription, cell proliferation and, as recently reported, 
in signaling and energy metabolism (Krishnakumar & Kraus, 2010; 
Yelamos et al., 2011; Kraus & Hottinger, 2013; Golia et al., 2015). 
Furthermore, PARP1 and PARP2 are involved in the first line of 
genome defense being efficient DNA-break sensors and signaling 
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molecules as a part of a survival program (Virág & Szabó, 2002; Beck 
et al., 2014). 
In human PARP1 the DNA binding domain (DBD) contains three zinc 
fingers to recognize DNA breaks; the central automodification domain 
(Domain E) has a motif (BRCT) for protein-protein interactions, and 
numerous glutamate residues for auto-poly(ADP-ribosyl)ation (auto-
PARylation). In human PARP2 the highly basic DBD has not zinc 
fingers and is structurally different from that of PARP1 likely 
explaining the differences in the recognized DNA structures. PARP2 
binds less efficiently to DNA single-strand breaks (SSB) but 
recognizes gaps and flap structures. Domain E (homologous to the E 
domain of PARP1), acts both as an automodification domain and as 
homodimerization interface (Schreiber et al., 2006; Steffen et al., 
2013).  
 
 
 
 
Figure 3: The domain structure of human PARP1 and PARP2.  
Domains (domains A-F) correspond to DNA-binding, automodification and catalytic 
regions. The PARP signature sequence (in dark blue within the F catalytic domain) 
is the most conserved between PARPs. ZnI and ZnII: Zinc-finger motifs. ZnIII: Zinc 
ribbon domain. NLS nuclear localization signal; BRCT BRCA1 carboxy terminus; 
NoLS nucleolar localization signal (Mégnin-Chanet et al., 2010). 
 
 
Interestingly PARP1 and PARP2 are themselves PAR acceptors, 
undergoing automodification (PAR-PARP) and acting as 
autoregulatory negative feedback (Krishnakumar & Kraus, 2010).   
PARP itself has been found to be the main acceptor of ADP-ribose 
polymers, both in vitro and in vivo (D’Amours et al., 1999). The 
enzyme acts as a dimer, and each monomer builds long and branched 
(up to 200 residues) ADP-ribose polymers (Amé et al., 2004). Once 
Introduction 
5 
 
the enzyme is activated, along with automodification, it can start a 
series of heteromodification reactions that modulate the functions of 
chromatin proteins (Muthurajan et al., 2014). However, besides 
binding to DNA, PARP interacts with other proteins and it has been 
shown that such interactions may depend on its automodification state 
(Griesenbeck et al., 1997).  
Strong evidence is provided for a specific relationship between DNA 
damage and acute depression of cellular NAD
+
 levels and that PARP1 
can influence metabolic homeostasis (Surjana et al., 2010; Faraone-
Mennella, 2015). PARP1 is a DNA damage sensor that can be 
activated in response to DNA damage by various patho-physiological 
conditions, including oxidative stress and inflammatory injury. The 
NAD
+
-consuming process is a consequence of PARP1 hyperactivation 
(Luo & Kraus, 2012; Kim et al., 2014).  
In the case of mild DNA damage, poly(ADP-ribosyl)ation facilitates 
DNA repair and thus survival. In the case of extensive one PARP1 
leads to depletion of NAD
+
 pools in cells upon hyperactivation, and 
attenuates NAD
+
 dependent ATP production, resulting in cell death 
(Jagtap & Szabó, 2005). When DNA damage is irreparable, PARP1 
activation induces the energy-dependent apoptotic process, by 
preventing ATP depletion and DNA repair through caspase-mediated 
PARP1 cleavage (Rolli et al., 2000; Surjana et al., 2010). In the case 
where PARP uses substantial amounts of its substrate, cells consume 
ATP in an attempt to replenish NAD
+
, this leads to a cellular energy 
crisis, which precipitates necrotic cell death (Virág & Szabó, 2002).   
During the apoptotic process, PARP is inactivated by caspase 3 by a 
single proteolytic cleavage of the 113 kDa active enzyme that 
produces an 89 kDa C-terminal fragment, with a reduced catalytic 
activity, and a 24 kDa N-terminal peptide, which retains the DNA 
binding domains, Figure 4 (Soldani & Scovassi, 2002; Aredia & 
Scovassi, 2014).  
PARP2 has been shown to be cleaved by caspase 8. PARP2 cleavage, 
similar to PARP1 cleavage, separates the DNA binding end-catalytic 
domains and inactivates the enzyme (Benchoua et al., 2002).  
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Figure 4: PARP1 and DNA damage (Surjana et al., 2010). 
 
 
Interestingly, PARP1 over-expression has been observed in various 
human tumour types and frequently correlated with a poor outcome, 
while the expression of PARP2 in cancer samples and its linkage with 
evolution of the disease is not completely known (Yelamos et al., 
2011). For instance, increased expression of PARP1 has been reported 
in the early stage of colorectal carcinogenesis (Nosho et al., 2006), 
intestinal adenomas of patients with familial adenomatous polyposis 
(Idogawa et al., 2005), hepatocellular carcinoma (Quiles-Perez et al., 
2010), endometrial hyperplasia (Ghabreau et al., 2004), breast, 
uterine, lung, and ovarian cancers (Ossovskaya et al., 2010).  
Moreover, poly(ADP-ribosyl)ation has a central role in inflammation. 
PARPs have been implicated in the regulation of immune functions by 
regulating the expression of inflammatory mediators such as 
cytokines, chemokines, adhesion molecules, nitric oxide synthase 
(iNOS) and cyclooxygenase 2 (COX2). Free radicals may cause DNA 
damage and activate PARP1 and PARP2 (Heller et al., 1994; Hegedűs 
& Virág, 2014). In case of severe DNA damage, PARP over-
activation may cause cell dysfunction which may contribute to 
inflammation. The association between inflammatory pathologies and 
PARP2 (Szántó et al., 2012), PARP3 (Phulwani & Kielian, 2008), 
tankyrases (Levaot et al., 2011), or PARP14 (Mehrotra et al., 2011, 
2013) has already been shown (Bai & Virág, 2012). 
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On the basis of these observations, the role of PARP as biomarker of 
DNA damage is widely demonstrated; PARP automodification is 
recognized a direct signal of DNA damage. Therefore, it is 
conceivable that its activity levels/expression in the cell nucleus can 
help in defining the physio-pathological state of the cell, offering a 
number of opportunities for therapeutic intervention in both cancer 
and other disease states (Morales et al., 2014). 
 
1.2 The lipidomics of cell membrane 
Lipidomics describes and quantitatively analyses the full complement 
of lipids, in the human body (body fluids, cells, tissues), and  
integrates these data with knowledge of their protein targets, i.e. the 
metabolic enzymes and transporters, and of the relevant genes and the 
regulatory aspects of these physiological systems. Lipids are energy 
biosources. Many intermediates of lipid metabolism serve a second 
function as primary or secondary messengers, under strict regulatory 
control. A variety of lipids serves to anchor proteins and glycans to 
membrane surfaces, thereby affecting and regulating their functions. 
Finally, lipids are the building blocks of cell membranes, providing 
these membranes with their physical characteristics. An understanding 
of cell membranes is only possible with a comprehensive 
understanding of their lipid constituents (Smilowitz et al., 2013). 
The cell membrane is highly organized and extremely important for a 
correct performance of the functions of the cell; it is a sensor that 
changes and adapts continuously to metabolic stimuli and the external 
environment (diet, stress, physical and chemical agents) and its 
properties are  regulated by fatty acid composition. The membrane FA 
asset, i.e., saturated (SFA), monounsaturated (MUFA) and 
polyunsaturated (PUFA), present in the phospholipids is characteristic 
of each tissue. A natural adaptation response is active and the 
appropriate changes of the FA microenvironment ensure the best 
functioning of membrane proteins, receptors, pumps and signals in 
tissues, according to environmental and metabolic needs 
(Chatgilialoglu & Ferreri, 2012). 
Fatty acids can be classified into saturated (SFA) and unsaturated, 
depending on the presence or absence of double bonds. The 
unsaturated are distinguished in monounsaturated fatty acids (MUFA), 
characterized by a single double bond, and polyunsaturated fatty acids 
(PUFA) that have two or more double bonds. The presence of double 
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bonds affects the structural properties of the membranes by increasing 
their fluidity and permeability, establishing the correct hormone-
receptor binding and membrane transporter functioning (Russo, 2009). 
Starting from the methyl group, defined as omega-one position, 
PUFAs are further subdivided in omega 3 (ω3) and omega 6 (ω6) fatty 
acids, depending on the position of the C atom were the first double 
bond occurs. 
In the human body α-linolenic acid, the precursor of the omega 3 
series, and linoleic acid, the precursor of omega 6 series, cannot be 
synthesized. Therefore, they are defined essential fatty acids (EFA); a 
correct diet will allow the intake of α-linolenic acid, and linoleic acid. 
The catalytic action of enzymes named desaturase and elongase, 
allows the conversion of these precursors to different intermediate and 
final products, which are eicosapentaenoic acid (EPA) and 
docosahexaenoic acid (DHA) for the omega 3 fatty acids, 
dihomogamma-linolenic acid (DGLA) and arachidonic acid (AA) for 
the omega 6 series, Figure 5 (Nakamura & Nara, 2004).  
EPA and DHA give rise to a series of products with anti-inflammatory 
effects, generally, with preventive effect against various diseases. In 
contrast, high concentrations of ω6 fatty acids, expecially AA, lead to 
an increase of pro-inflammatory stimuli (Caramia, 2008).  
The importance of the ω6/ω3 ratio has been evoked not only in the 
inflammatory and cardiovascular pathologies, but also in cancer and 
autoimmune diseases (Russo, 2009; Sheppard & Cheatham, 2013). 
EFAs, being precursors of AA, play a crucial role in the synthesis of 
prostaglandins (PGs) by a cyclooxygenase (COX) enzyme. The 
alteration of this process would seriously affect many normal 
metabolic processes. Two COX isoforms have been identified, COX1 
enzyme is expressed constitutively in most cells and tissues under 
either physiological or pathological conditions, COX2 is normally 
absent from most cells but highly inducible in certain cells in response 
to inflammatory stimuli resulting in enhanced PG release. It is 
suggested that consumption of a diet enriched in ω3 PUFA 
(specifically EPA and DHA) and inhibition of COX2 may confer 
cardioprotective effects and provide a significant mechanism for the 
prevention and treatment of human cancers (Tapiero et al., 2002). 
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Figure 5: Biosynthesis of omega 6 and omega 3 PUFAs.  
 
 
The synthesis of AA-derived eicosanoids is influenced by the 
concentration of DGLA. The excess of DGLA competes with AA for 
COX and lipoxygenase (LOX), inhibiting the production of AA-
derived eicosanoids and driving the synthesis of DGLA-dependent 
prostaglandins (Dooper et al., 2003). 
Increased ω6 and reduced ω3 long-chain PUFA (LC-PUFA) intake in 
diets may contribute to the increased prevalence of allergic diseases. 
The ω6 LC-PUFA AA enhanced pro-inflammatory mediator 
production by effector cells in allergy (mast cells), while the ω3 LC-
PUFA EPA as well as DHA more effectively suppressed reactive 
oxygen species (ROS) generation and interleukin-4 (IL-4) and 
interleukin-13 (IL-13) release. This suggests that dietary 
supplementation with EPA and/or DHA may alter the mast cells 
phenotype, contributing to a reduced susceptibility to develop and 
sustain allergic disease (van den Elsen et al., 2013). Also, oral 
supplementation of the PUFA AA and DHA together with 
galactooligosaccharide and polydextrose (GOS and PDX) ameliorates 
the disturbed epidermal skin barrier of allergen-induced dermatitis due 
to a reduction in the local inflammatory immune response; the 
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normalization of the skin status is most likely dependent on direct 
action of DHA/AA or their bioactive metabolites on keratinocytes and 
mast cells (Weise et al., 2013). 
Recent studies have shown that ω3 polyunsaturated fatty acids 
(PUFA) and statins have antiviral properties in vitro (Sheridan et al., 
2014). AA, DHA and EPA inhibit hepatitis C virus (HCV) replication 
in vitro using the HCV RNA replicon system. ω3 PUFAs may inhibit 
HCV replication in vitro by a mechanism that is independent of their 
ability to suppress lipogenic gene expression (Kapadia & Chisari, 
2005). 
Lipids and phospholipids are the most susceptible molecules to stress 
conditions, including lipid remodelling and ROS attack, with 
consequent changes of fatty acids contents. 
It is worth mentioning that in humans the unsaturated fatty acids 
(MUFA and PUFA) have the unsaturations (double bonds) in the cis 
configuration, displaying a bent structure that is very important for  
the fluidity of membranes.   
The radical stress can induce an alteration in the normal cis 
configuration, leading to the formation of trans isomers, with a 
straight aliphatic chain (Figure 6). This different geometric disposition 
causes a greater membrane packing by altering its biological and 
biophysical properties. The consequences can affect metabolism and 
pathological processes.  
 
 
 
 
Figure 6:  cis and trans fatty acid isomers.  
 
 
Therefore the knowledge of the membrane status can be very 
important for the evaluation of the overall metabolic functioning 
(Ferreri & Chatgilialoglu, 2012).  
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In this context, lipidomics study membrane lipids, comparing their 
quality and quantity in relation to physiological and pathological 
conditions of the membranes. Membrane fatty acid composition is 
typical for each tissue and particularly the erythrocyte membrane has a 
peculiar percentage distribution of fatty acids and its lipid composition 
reflects the constant behavior in diet and the status of the subject.  
The important role of changes to the membrane structure and 
corresponding physical-chemical properties are well established (van 
Ginkel & Sevanian, 1994).  
Changes in the packing of membrane components, molecular 
redistributions, increased permeability, lateral fluidity, occur upon 
membrane reorganizations following oxidation of lipids by ROS, by 
influencing the conformations and thus the functions of selected 
membrane proteins, and leading to pathological conditions 
(Simopoulos, 2002; Baritaki et al., 2007; Calder, 2009). 
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1.3 Scientific hypothesis and aim of the work 
PARP automodification and membrane fatty acid composition are 
molecular aspects which can be taken as the mirror of the 
healthy/pathological state of the cell. In fact they both have been 
independently used in the last decade by several authors to look at 
membrane status and DNA damage in the cell. 
Our working hypothesis is that combining the measure of lymphocyte 
PARP automodification (PAR-PARP levels) with erythrocyte 
membrane lipid profile (fat profile), allows to draw either prognostic 
or diagnostic clinical picture to support therapeutic and/or 
nutraceutical approaches. Despite many evidence available in 
literature suggest that increased oxidative stress and genomic 
instability can be monitored as early signals for prevention, these 
molecular aspects have not been examined in epidemiological and 
clinical settings yet. 
Aim of the present research was to study the possibility that the two 
methods applied together in the laboratory routine could represent non 
invasive tests to determine the physio-pathology of cells by using 
venous blood as source of erythrocytes (for membrane fatty acid 
profile) and lymphocytes (for detection of automodified PARP levels).  
The analyses were performed on a cohort of subjects recruited at the 
Department of Clinical and Surgical Medicine  (University of Naples 
“Federico II”) for blood samples and clinical profiles. 
The research was developed in three phases. First the samples 
underwent blindly to both tests. In the second phase, the results were 
compared with anamnestic and clinical data, and tabulated. Lastly, all 
data underwent statistical analyses. The initial statistic analysis was 
done after 70 individuals were examined. This number further 
increased up to 95 subjects. Two approaches were followed: first, a 
series of statistical analyses were performed grouping the subjects on 
the basis of their body mass indexes (BMI); thereafter the same 
people, implemented with new samples, were considered statistically 
on the basis of their pathologies. The latter results were used to find 
out any correlation between the two tests and the occurring diseases. 
The rationale of BMI analysis (first approach) arose from the 
observation that overweight and obesity have recently reached vast 
proportions worldwide, representing one of the main historical 
metabolic risk factors. The onset of these conditions of excess weight 
has remarkable effects on health status with an increased risk of 
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inflammatory and cardiovascular diseases and some cancers. In this 
context, the first evaluation criterion was the comparison of the results 
of the analyses with both anthropometric measures (body mass index) 
and any clinical state of subjects undergoing the survey. 
Second, a statistical analysis followed to evaluate the possible 
correlation of PARP automodification values with the clinical data 
and lipid profiles of the subjects, with the aim to study whether these 
analyses can have a predictable and/or early diagnostic meaning. 
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2. Materials and Methods  
The volunteers (95) object of this survey, ageing 20-80 years, were 
recruited at the Department of Clinical Medicine and Surgery for 
interview, blood collection and routine diagnostic and clinical 
analyses. They underwent endoscopies either to confirm or to get 
diagnosis of intestinal pathologies. They all signed an informed 
consent for anonimous treatment of their data, according to the 
privacy rules. 
Blood (8 ml) was collected by venipuncture in the presence of EDTA 
and aliquoted. One aliquot (4 ml) was used within few hours to 
prepare lymphocyte fraction. The second aliquot was used for 
erythrocyte membrane fatty acid composition. 
 
2.1 Lymphocyte preparation and lysis 
All operations were performed at 4°C. 4 blood aliquots (1 ml) of each 
sample were separately used to prepare lymphocytes, after counting 
the cells per ml of blood by hematic cell counter. In this way taking 
into account a comparable loss of lymphocytes during preparation 
under the same conditions for all samples, the results were referred to 
the initial number of cells/ml.  
Lymphocytes were prepared according to GE Healthcare protocol, 
provided with Ficoll. Briefly each blood aliquot (1 ml) was layered on 
a Ficoll-Hypaque (GE Healthcare) cushion (1:0.7, v/v) and 
centrifuged at 2,500 rpm for 10 minutes. Because of their lower 
density, the lymphocytes were found at the interface between the 
plasma and the Ficoll-Paque PLUS with other slowly sedimenting 
particles (platelets and monocytes). The lymphocytes were recovered 
from the interface and subjected to short washing steps to remove any 
platelets, Ficoll-Paque PLUS and plasma. Crude lymphocyte fraction 
was washed twice with 0.9% NaCl, followed by 10 min centrifugation 
at 1,500 rpm. Pelleted pure lymphocytes were suspended in 0.9% 
NaCl (100 µl/blood ml). Few microliters of the suspension were used 
for counting pure lymphocytes. In general a 20% loss was measured. 
Pure lymphocytes were often used as freshly prepared fraction or 
stored at -80°C until used. Cells from 1 ml blood were lysed by 
suspension in lysis buffer (300 μl; 10mM Tris-HCl pH 7.5, 1% 
Nonidet P40, 2mM Spermidine-HCl, 10mM Na2EDTA, protease 
inhibitor cocktail 2μg/ml (Sigma), 1mM Phenyl Methyl Sulphonyl 
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Fluoride, PMSF) and incubation for 30 minutes at 4°C. The whole 
lysate was further analysed. Protein content was determined by 
Bradford’s reagent (Bio Rad) according to the provided instructions. 
In order to determine whether increased PAR-PARP levels 
corresponded to damaged DNA, few cells from three normal and three 
PAR-PARP altered samples underwent to comet assay according to 
Atorino et al. (2001) and D’Onofrio et al. (2011). This technique is 
routinely performed on single cells by a research group at the 
Department of Biology. 
 
2.2 SDS-PAGE and immunoblotting 
 
 2.2.1  Immunochemical analysis  
Immunochemical analysis were performed blindly on blood samples 
collected from both healthy people and patients with different 
pathologies, according to Faraone-Mennella et al. (2010). Polyclonal 
anti-PARP1 catalytic site antibodies (H-250, Santa Cruz) were used to 
evidence PARPs.  
The highly conserved catalytic domain allowed to recognize any 
PARP with these antibodies.  
 
Alkali incubation of automodified PARP (PAR-PARP) was carried on 
in 10mM Tris-HCl pH 9.5, for three hours at room temperature, 
optimal conditions for complete removal of the polymer from the 
acceptor protein.  
 
 2.2.2 Densitometric analyses 
Automodified PARP was quantified by densitometric analyses of 
immunobands with a Chemidoc apparatus (Bio Rad) and expressed as 
optical density (OD, i.e. intensity of a band)/mm
2
.  
To measure the densitometric value a rectangle was drawn encircling 
the band to quantify. The area of the rectangle was always constant. 
Therefore the variable parameter was the intensity of the band. Even if 
the Quantity One program software automatically subtracted a mean 
value of the densities measured all over the filter (blank), a 
background value was manually subtracted. This manual blank was 
measured by using the above described rectangle on a zone of the 
filter without bands. In addition, the results were normalized by 
performing densitometric measures of images with the same time of 
Materials and Methods 
16 
 
development and chemiluminescent capture signals, as determined by 
preliminary analyses. In this way the results could be easily compared 
for all experiments. 
 
2.3 Membrane fatty acid determination 
An aliquot (4 ml) of each blood sample was used for the fatty acid 
analysis of erythrocyte membrane performed by the procedure 
described in Ghezzo et al. (2013). 
This procedure is effected by an automatism set up at Lipinutragen 
(Ferreri, 2008), a spin-off company of the National Council of 
Research (CNR) in Bologna (Italy), connected with the calculation of 
the membrane unbalance index. 
 
2.4 Body mass index 
Body mass index (BMI) measured body height and weight of adult 
men and women to screen for weight categories that may lead to 
health problems, classified as under-, normal-, over-weight and obese. 
It was calculated as the ratio between weight in kilograms divided by 
the square of the height in meters (kg/m
2
). The antropometric data, 
known only for 84 of 95 subjects, allowed to calculate their body mass 
indexes (BMI). On this basis three groups were identified: normal 
weight (19<BMI<25); overweight (25<BMI<30); obese (BMI>30). 
 
2.5 Statistical analyses 
Statistical analyses were performed using Microsoft Excel and Graph 
Pad Prism Programs. 
The data were statistically analyzed with both parametric and non 
parametric tests. 
The applied parametric procedures, as ANalysis Of VAriance, 
ANOVA, rely on assumptions about the shape of the distribution (i.e., 
assume a normal distribution) in the underlying population and about 
the form or parameters (i.e., means and standard deviations) of the 
assumed distribution (Conover, 1980; Rosner, 2000). ANOVA 
allowed to identify whether there are significant differences between 
the means of three or more independent (unrelated) groups. In the 
context of medical statistics, Receiver Operating Characteristic (ROC) 
curve, based on a parametric approach, has become the method of 
choice for quantification of accuracy of medical diagnostics tests 
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(Erdreich & Lee, 1981; Henderson, 1993). It is widely applied in 
measuring discriminatory ability of diagnostic or prognostic tests. 
For multivariate complex problems, when the distribution model is not 
known, and the sample size is less than the number of variables, it is 
useful to change from a parametric approach to a non parametric one. 
Non parametric tests are the Chi square (χ² test), based on the 
frequencies, and the Mann Whitney U-test based on sorting of the 
information. Chi-square is used to compare observed data with those 
expected according to a specific hypothesis. The Mann Whitney U-test 
allows to know whether two independent samples of observations are 
drawn from the same or identical distributions. 
Spearman’s Correlation was applied too. 
Details of ROC curve, Mann Whitney U-test, Spearman’s rank 
correlation coefficient are reported below. 
 
 2.5.1 Receiver Operating Characteristic (ROC) curves 
ROC curves are constructed by computing and comparing the 
sensitivity (y‐axis) and specificity (x‐axis= 1-specificity) of increasing 
numbers of clinical findings. High sensitivity corresponds to high 
negative predictive value; high specificity corresponds to high positive 
predictive value. 
An important measure of the accuracy of the clinical test is the area 
under the ROC curve (AUC) that measures discrimination, i.e the 
ability of the test to classify correctly those with and without the 
disease (Zweig & Campbell, 1993). If this area is equal to 1.0 then the 
ROC curve consists of two straight lines, one vertical from 0.0 to 0.1 
and one horizontal from 0.1 to 1.1. A ROC curve that is the diagonal 
line from 0.0 to 1.0 corresponds to a test that cannot discriminate 
between normal and abnormal subjects. Area for this line is 0.5. The 
greater the area under the curve, the better is the discriminatory power 
of the test. Significant ROC curve areas are typically between 0.5 and 
1.0 (Swets, 1988). 
 
 2.5.2 Mann Whitney U-test 
The results of the ROC curves were validated with the non parametric 
Mann Whitney U-test, that verifies the significance of the differences 
among medians (Soliani, 2001). The U-test is based on the 
precedences’ number. Considered two groups (A and B), a correct 
count is how many times each data of A group is preceded by data of 
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B group. The lowest amount of precedences is the U value. If the two 
groups belong to different populations, the median of a group is 
considerably less than the other, and the value of U will tend to 0.  
The test is significant (α ≤ 0.05/0.01) when the calculated value of U 
is less than or equal to the tabulated value, considering the size of 
groups (n1 and n2), Table 1. 
 
 
Table 1: Critical values of the Mann Whitney U-test. 
 
 
The values refer to the probability of α ≤ 0.05/0.01 (n1= group with a 
lower number of cases; n2= group with a greater number of cases). 
 
 
 2.5.3 Spearman’s rank correlation coefficient 
Spearman’s rank correlation coefficient is used to identify and test the 
strength of a relationship between two sets of data. 
The Spearman correlation coefficient, ρ (rho), can be calculated when 
the two variables (X; Y) are in terms of ranks. The null hypothesis is 
that ρ is 0. A ρ= 0 means that the ranks of one variable do not co-vary 
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with the ranks of the other variable; in other words, as the ranks of one 
variable increase, the ranks of the other variable do not increase (or 
decrease). 
If the change in one variable brings about a change in the other 
variable, they are said to be correlated. A ρ= +1 means that the two 
variables are directly correlated (low values of X correspond to low 
values of Y); A ρ= -1 means that the two variables are indirectly 
correlated (high values of X correspond to low values of Y) (Soliani, 
2001). 
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3. Results  
 
3.1 Analyses of PAR-PARP and membrane lipid profiles 
 
 3.1.1 PAR-PARP  
Automodification of PARP (PAR-PARP) was evidenced by 
immunoblotting with polyclonal anti-PARP catalytic site antibodies 
(PARP-CSAbs). These Abs allowed to visualize the enzyme in both 
native and modified form. Figure 7 shows the patterns of unmodified 
PARP from three analysed samples (Figure 7A, a, lanes 1-3). In the 
absence of automodification the immunoband corresponded to native 
PARP. In Figure 7A (b, lanes 1-3) three examples of automodified 
PARP (PAR-PARP) from other samples are shown. PAR-PARP gave 
signals above 113 kDa. The shift of molecular mass accounted for 
more than hundred ADP-ribose molecules modifying the enzyme. 
A worth noting result was that in lymphocytes the PARP enzyme 
involved in automodification was mainly PARP2 (62 kDa; Figure 7A, 
a).  
Confirming this finding was an experiment where PAR-PARP was 
excised from the gel and the slice incubated under alkali conditions. 
The ester bond between protein and the first unit of poly(ADP-ribose) 
is highly sensitive to alkali treatment. The polymer-free PARP was 
eluted, electrophoresed and re-analysed by the same antibodies 
(Figure 7B); it gave a band shifted from high molecular weight (above 
113 kDa), to 62 kDa, the molecular mass of PARP2 (Figure 7B, 1’-
3’). 
Following this experimental procedure, the lymphocyte PARP was 
analysed for all subjects and the amount of automodification was 
measured by densitometry of the bands, expressed as optical 
density/mm
2
 (Figure 7C). DNA damage levels of the samples with 
high PAR-PARP were measured by comet assay (data not shown). 
The results confirmed that PARP automodification increased as 
consequence of DNA breaks. 
Being the level of PARP automodification a measure of DNA 
damage, the results of densitometry allowed to classify subjects 
according to the extent of DNA damage. 
Controls were identified from anamnestic data, whose levels of PAR-
PARP allowed to define the limits of variability of the reference 
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range. The pathological samples were analyzed and compared with the 
controls. The density of immunopositive bands of pathological 
samples were higher than the controls, and differed from each other, 
indicating different levels of DNA damage.  
The lymphocyte PARP was analyzed for all subjects and the results 
were grouped according to automodification levels: OD<20000 
int/mm
2 
corresponded to physiological PAR-PARP (PA); 
20000≤OD≤40000 int/mm2 indicated moderate levels of PAR-PARP 
(MA); hypermodification of PAR-PARP (HA) gave OD>40000 
int/mm
2
.  
 
 
         
 
 
 
Figure 7: Anti-PARP catalytic site immunoblotting of lymphocyte lysates.  
Panel A, anti-PARP immunoblottings of three samples with native (a) and 
automodified (b) PARP. Panel B. Immunopatterns in A, (b), before (1, 2, 3) and 
after (1’, 2’, 3’) alkali incubation of PAR-PARP. In 1’, 2’, 3’ poly(ADP-ribose)-free 
PARP localizes at the molecular mass of native enzyme. Panel C. Densitometric 
analysis of immunoblots of control samples (black) and pathologic (gray) of the 
panel A(a) and A(b), respectively.  
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 3.1.2 Membrane fatty acid analysis 
The erythrocyte membrane has a characteristic FA asset, i.e., saturated 
(SFA), monounsaturated (MUFA) and polyunsaturated (PUFA), 
cis/trans isomers, all present in specific amounts in the phospholipids 
of the bilayer. 
The response of lipid analysis is the FAT PROFILE, a table with the 
fatty acid values found in the erythrocyte membranes in comparison 
with the normal values (Table 2). The values are expressed as a 
relative percentage (% rel) of the total fatty acids considered.  
 
 
Table 2: Main fatty acids and optimal intervals determined 
in the erythrocyte membrane of healthy subjects.  
 
 
 
 
Table 2 includes the main SFA (Palmitic and Stearic acids), MUFA 
(Palmitoleic and Vaccenic acids)  and the main PUFAs. From these 
values it is possible to calculate the SFA/MUFA and ω6/ω3 ratios. 
The ratio SFA/MUFA can indicate biosynthetic and dietary 
contribution, which create the balance between these two FA families 
in the membrane compartment, regulating structural organization, 
biophysical properties and functioning. The harmful consequences of 
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an excess of SFA for health is known, as well as favorable membrane 
biophysical properties of fluidity and permeability, and biochemical 
functions and signaling cascades, depends on the natural double bond 
content (MUFA, PUFA). It is worth underlining that the unsaturated 
content is correlated to the functioning of enzymes, namely Δ5-, Δ6- 
and Δ9-desaturases involved in PUFA metabolism. Fat profile is a tool 
to check either FA enzyme metabolic pathways and the pro- and anti-
inflammatory state of the cell. Moreover this analysis is able to 
measure the levels of trans-PUFA, a direct index of oxidative stress.  
The profile is completed with a graphic to connect the measured 
values with anamnesis and metabolism of the patient (Figure 8A), and 
with a Membrane Unbalance Index (MUI) that, by an algorithm 
visualized by a color scale, summarizes simply the FA unbalance 
percent (Figure 8B). For the Italian population, the reference values of 
erythrocyte membrane fatty acids have been described and are 
reported in Table 2. 
 
 
 
 
Figure 8: A. Fatty acid profile of a subject (orange line) compared to normal 
ranges (green zone). B. Membrane Unbalance Index (MUI) and colored scale. 
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3.2 Relationship of PARP automodification and membrane lipid 
composition with lifestyle and health status 
The study performed on 84 subjects undergoing endoscopy, by 
detecting PAR-PARP levels and analyzing erythrocyte membrane fat 
profiles, started monitoring the physio-pathological state of the cell, 
and its possible correlation with lifestyle, diet or diseases. 
In the following paragraphs the results of PAR-PARP levels and fat 
profiles are reported and statistically evaluated separately. 
 
 3.2.1 Automodification of PARP 
The number of analysed subjects changed over time. The lymphocyte 
PARP was initially analyzed for 70 subjects; thereafter this number 
increased to 84. The results were grouped according to 
automodification levels: OD<20000 int/mm
2 
corresponded to 
physiological PAR-PARP (PA); 20000≤OD≤40000 int/mm2 indicated 
moderate levels of PAR-PARP (MA); hyper-modification of PAR-
PARP (HA) gave OD>40000 int/mm
2
.  
The results of analysis of variance were comparable for both the 70 
subjects and the same group increased to 84 samples (Figure 9B).  
By this analysis the difference between PA, MA and HA was 
statistically significant (Figure 9A).  
 
 
 
 
Figure 9: Analysis of variance of PAR-PARP levels.  
A. PA, Physiological PAR-PARP (n=24); MA, Moderate PAR-PARP (n=21); HA, 
High PAR-PARP (n=25). B. PA (n=28); MA (n=22); HA (n=34). 
A high statistical significance of the difference between the three groups was 
calculated, with P<0.0001. 
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The three groups had values significantly different each other; the 
PAR-PARP level range was narrow in PA and MA groups, whereas 
those of HA group were distributed in a wider range. These ranges 
were reduced by increasing the number of subjects from 70 to 84 
(Figure 9B). However, the difference between the three groups was 
still statistically significant. 
Increased PAR-PARP levels were measured in case of inflammation, 
viral infections and cancers with a relevant clinical activity (no 
surgical or therapeutic treatment, presence of metastases). As opposite 
PA was measured in healthy and remitting patients. 
On this basis the first analytical approach was to group the data by 
BMI. Three groups were identified: normal weight (19<BMI<25; 
NW); overweight (BMI<30; OW); obese (BMI>30; O). 
The comparison of PAR-PARP levels with BMI groups (NW, OW, O) 
gave, either within each group or between the three groups, P values 
highly above 0.1, i.e. the difference was not statistically relevant 
(Figure 10). χ2 test confirmed this behavior (Table 3). Similar results 
were obtained, comparing PAR-PARP levels and the age of volunteers 
(data not shown). 
 
 
 
 
Figure 10: PAR-PARP levels in BMI groups. 
NW=normal weight (n=22); OW=overweight (n=41); O=obese (n=21). The 
difference between groups was not significant (P>0.05). 
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Table 3: χ2 non parametric test of PAR-PARP compared to BMI of subjects. 
 
 
  NW. Normal weight; OW. Over weight; O. Obese. 
                       n= number of cases.  
 
 
In conclusion, even before performing other more complex diagnostic 
analyses, and in accordance with data from literature, DNA damage is 
easily detectable by PAR-PARP measures and is independent from 
anthropometric data.  
 
However, by grouping the examined subjects in three ranges of age 
(years 20-39; 40-59; >60) and considering anamnestic data, the results 
of Table 4 were obtained.  
 
 
Table 4: Age-related PAR-PARP levels. 
 
 
Percentage (%) refers to the number of affected subjects per each group of PAR-PARP 
levels. 
HPV: Human Papilloma Virus; HCV: Hepatitis C virus.  
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The youngest people (years 20-39) showed mainly moderate PAR-
PARP, at the highest percentage (50%) for allergy, and 25% for either 
smoking or dyslipidemia/hypertension. The latter increased to 60% 
and 80% for the other two ageing groups (40-59, >60, respectively). 
High PAR-PARP (HA) had noticeable incidence at any age for 
adenomas, autoimmunity and HCV/Papilloma virus infections. It 
occurred in 15% of aged (years >60) patients with cancer. 
Physiological levels of PAR-PARP were measured either in the 
absence of diseases, or in cases of diseases under remission or 
therapeutic treatments. It is worth noting that both moderate and high 
PAR-PARP levels were observed mostly in subjects with 
inflammatory conditions of lower or higher gravity (Table 4), but all 
relatable to different DNA damage extents.  
 
  
Results 
28 
 
3.2.2 Membrane lipid profile (fat profile) 
The fatty acids taken from fat profiles as indexes of cell functions and 
metabolism included the main SFA and MUFA, and omega 3 (EPA, 
DHA), omega 6 (DGLA, AA). In order to evidence specific features 
of FA metabolic enzymatic pathways, the ratio of SFA/MUFA, and of 
ω6/ω3 PUFA were considered. In particular, on the basis of normal 
values indicated by fat profile, three groups of subjects were 
identified: physiological, with FA within the normal range; < min, for 
those subjects with values below the lowest range limit;  > max, if the 
values were above the highest range limit (Table 5, A-C). A further  
subdivision was made by considering the three BMI groups (NW, 
OW, O), Table 5 (A-C). In this way for each BMI group it was 
possible to highlight both the different unbalance level of fatty acids 
and the number of patients with altered FA amounts.  
 
 
Table 5: Different levels of the main fatty acids in NW (A), OW (B) and O (C) 
groups. 
 
  A. Normal weight (n= 22) 
 
Normal ranges of FA (%): SFA/MUFA (1.7-2); ω6/ω3 (3.5-5.5); EPA (0.5-0.9); DHA (5-7); 
DGLA (1.9-2.4); AA (13-17). 
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  B. Overweight (n= 41) 
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  C. Obese (n= 21) 
 
 
 
SFA/MUFA ratio. The unbalance of SFA/MUFA ratio occurred for 
all subjects grouped for BMI. An increase of SFA was recorded for 
almost all the normal weight subjects (86% of cases); the values were 
within the normal range for 14% people; no patients had SFA levels 
lower than normal values.  
In overweight subjects 88% SFA/MUFA ratios were altered, whereas 
12% ones were physiological.  
The same trend was recorded in the obese group. Except for one 
subject, the other ones showed an increase of SFA/MUFA ratio. 
ω6/ω3 ratio. Excessive values of ω6 were found in more than half of 
the normal weight people; physiological measures were found in 32% 
of case; only one subject had a lower ω6/ω3 ratio. The increase in the 
ratio was mainly due to low levels of DHA in 14 of 22 people. The 
levels of EPA and AA fell within in the normal ranges for almost all 
subjects, (59%, and 82% of cases, respectively). Physiological DGLA 
values were found for only 45% of cases. 
Physiological levels of ω6/ω3 ratio were measured for 86% of OW 
subjects, they were due to the normal values of EPA, DHA, and 
DGLA found in over half of the group (for 26, 25 and 21 of 41 people, 
respectively).  
The slight increase of the ω6/ω3 ratio for 52% of the obese subjects 
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was mainly due to a decrease of DHA values for 67% of them. 
AA was within normal range in almost all the subjects of the three 
groups. 
The unbalance of the ratios of SFA/MUFA and ω6/ω3 PUFA were 
highlighted in graph (Figure 11, A-C). The values were compared to 
the normal ranges, drawn by the horizontal lines to the x axis. In any 
BMI group there was a plain unbalance of SFA/MUFA ratios 
compared to the control values; even the ω6/ω3 ratio was altered in 
the majority of subjects recruited, regardless of BMI. χ2 test confirmed 
these results (Table 6). 
These results at least allow correcting the quality of food, limiting the 
intake of nutritional sources of SFA, in order to re-establish the right 
content of these FA categories. Thereafter, it is possible to evaluate 
whether there might be alterations in any enzymatic step of FA 
metabolism requiring further attention. 
A high unbalance was measured for ω6/ω3 PUFA. In some cases, 
there was a net increase of arachidonic acid, a precursor of many pro-
inflammatory compounds, compared to the expected normal ranges. 
Mostly a high reduction of ω3 PUFA was observed. Due the anti-
inflammatory value of these FA, their deficiency indicated a low anti-
oxidant defense ability of cells, and a high risk of inflammation.  
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Figure 11: SFA/MUFA and ω6/ω3 PUFA unbalance in the recruited 
volunteers.  
The values measured for each patient versus normal values for the three BMI groups: A. 
Normal Weight; B. Over Weight; C. Obeses.  
SFA/MUFA          ω6/ω3     
 Cut off of normal ranges SFA/MUFA      and ω6/ω3   
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Table 6: χ2 non parametric test of SFA/MUFA ratio compared to BMI of 
subjects. 
 
 
 NW. Normal Weight; OW. Overweight; O. Obese.  
                    n= number of cases. 
 
 
 
 3.2.3 Correlation between PAR-PARP results and fat profiles in 
BMI groups 
In order to answer one of the question stated by the aim of this work, 
the results obtained by the two analyses were statistically evaluated to 
check whether they could correlate each other, and be used in 
combination to detect the physio-pathological state of the cell. The 
Spearman test was performed, giving the results shown in Table 7. 
Taking into account that the Spearman’s rank correlation coefficient 
(ρ) is the main parameter, and that values of ρ equal to 1 indicate a 
direct correlation, whereas values of -1 show an indirect correlation, 
the test did not reveal a significant correlation in any of three groups 
(Table 7). 
The results described in section 3.2.1 indicated that PAR-PARP levels 
allow to detect DNA damage occurrence, that is independent from 
anthropometric data.  
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Table 7: Correlation between PAR-PARP levels and fat profile in BMI groups. 
 
 
A. Normal weight 
 
 
 
B. Overweight  
 
 
 
C. Obese  
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3.3 PARP automodification and membrane lipid composition in 
patients with inflammatory pathologies 
The rationale of the second approach used to evaluate the results of 
both analyses obtained for 95 subjects was to consider them in 
relationship with clinical data, i.e. upon possible occurrence of any 
pathology. Therefore, the data were treated independently from BMI, 
taking into account the declared/diagnosed diseases. 
This phase of the work was developed following the steps of the 
previous chapter (3.2). First, non parametric tests were performed for 
results of PAR-PARP measures by comparing the altered values with 
the physiological ones.  
Second, fat profile results were statistically evaluated by comparing 
unbalanced levels of FA with the normal ones. In this second phase of 
the work the attention was focused mainly on PUFAs (EPA, DHA, 
DGLA, AA), considered as single FAs, rather than only on the ratio of 
SFA/MUFA and ω6/ω3.  
Third non parametric tests were performed to study the possible 
correlation of the two combined analyses, PAR-PARP and fat profile, 
towards a given pathology. 
The results of the molecular analyses (PAR-PARP and fat profile) 
were compared with anamnestic and clinical data of the  volunteers 
(84 subjects of the previous analyses, reported in section 3.2, plus 11 
new patients).  
All these subjects were different as some ones had no pathology, few 
ones had a single pathology, and a larger number declared more than 
one disease. It was necessary to enclose them in different groups and 
subgroups as detailed below. In this way groups and subgroups were 
often composed of few subjects. For this reason, non parametric tests 
had to be used in order to perform rightly statistical analyses. They 
gave the results described in the following sections.  
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 3.3.1 Groups of enrolled subjects 
In Table 8 general information of the 95 subjects is highlighted. 
 
 
Table 8: Distribution of recruited subjects (n=95) by gender,  
age and some lifestyle habits.  
 
 
 
 
6 subjects out of 95 had no pathology as stated in their interviews and 
confirmed by clinical analyses; by comparison of  these data with 
PAR-PARP and fat profile, they were considered as controls 
(healthy).  
The subdivision of patients in different groups was first made on the 
basis of the diagnosed/declared disease, if unique, or the most serious 
one occurring and then, within the same pathology, subgroups were 
identified, starting from patients with a single disease. In those cases 
where pathologies of a different type were co-present, a separate 
subgroup named “mixed” was considered.  
The subjects were grouped as reported in Table 9. Group 0 
corresponded to volunteers without diseases as a result of their 
statement and from clinical and diagnostic analyses. This group was 
taken as healthy.  
The most numerous group enclosed patients with gastro-enteric 
diseases (group 1, n=37). Subjects in the subgroup 1a had diagnosis of 
simple or hyperplasic polyposis; patients in the subgroup 1b showed 
adenomas and hyperplastic polyps; the subgroup 1c consisted of 
patients affected by non-cancerous gastrointestinal disorders; patients 
in the subgroup 1d were affected by gastro-enteric cancer; those of the 
subgroup 1e had other disorders along with the cancer and were 
defined “mixed”.  
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Group 2 was composed of patients with mild thyroid disorders (2a), 
subjects with the autoimmune Hashimoto’s thyroiditis (2b) and the 
“mixed” ones with thyroid disorders and other diseases (2c). The 
groups of patients affected by allergies and HCV were divided into 
two subgroups including the “mixed”.  
The remaining subjects were grouped as affected by autoimmunity 
(group 5), no gastro-enteric cancer (group 6), cardiopathy (group 7), 
dyslipidemia/hypertension (group 8). Details of diseases in each group 
are given in the footnote to Table 9. 
 
 
Table 9: Groups of patients. 
 
 
 (1e): cancer GE, thyroid disorders, allergy, hypertension, dyslipidemia;  
 (2c): thyroid disorders, allergy, hypertension, dyslipidemia, polyposis; 
 (3b): allergy, hypertension, uterine fibroid, reflux; 
 (4b): HCV, thyroid disorders, polyposis, hypertension, adenoma, cancer, 
cardiopathy, dyslipidemia. 
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 3.3.2 Statistical analysis by Receiver Operating Characteristic 
(ROC) curve 
 
 3.3.2.1 ROC curves of controls 
The values of  PAR-PARP and EPA, DHA, DGLA, AA of the control 
subjects (group 0) were compared to the levels of physiological PAR-
PARP and normal PUFAs known from literature. Figure 12 shows 
their ROC curves. The areas below the curves of controls (healthy) 
had values equal or close to AUC 0.5, meaning that they could be 
considered as physiological. Indeed they were taken as reference to 
evaluate the statistical significance of the data obtained for the other 
groups. 
 
 
 
 
Figure 12: ROC curves of PAR-PARP levels and PUFAs to define control 
subjects. 
 
 
The area of PAR-PARP was exactly 0.5, whereas PUFAs gave a 
maximum of  0.57, taken as an index of unbalance in non pathological 
conditions possibly related to lifestyle.  
These results indicated that the six subjects identified as controls had 
PAR-PARP and PUFA levels within or slightly out the physiological 
values reported in literature. 
Results 
39 
 
 3.3.2.2 Analysis of PAR-PARP data by ROC curves  
The results of automodified PARP from each group, compared to 
group 0 (controls), were statistically evaluated by drawing the 
corresponding ROC curve (Figure 13). 
 
 
 
 
Figure 13: ROC curves of PAR-PARP levels in subjects with different 
pathologies. 
 
 
In most of the groups and subgroups the ROC curve areas of PAR-
PARP were higher than 0.7. Except for the subgroups of subjects with 
polyposis (1a) and mild thyroid diseases (2a). A very slight 
significance was evidenced for infections, thyroid diseases, cancers 
under treatment and GE carcinomas. Areas under ROC curves highly 
increased mainly in HCV and GE adenomas. Intermediate values were 
observed for the other groups.  
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 3.3.2.3 Analysis of PUFAs by ROC curves 
The ROC curve was determined for EPA, DHA, as ω3, and DGLA, 
which is the ω6 FA at the cross-road between pro-inflammatory (AA 
biosynthesis) and anti-inflammatory (PGE2 biosynthesis) pathways. 
Figures 14, 15 and 16 show, respectively, the ROC curve areas of 
EPA, DHA, and DGLA, for the different groups compared to their 
controls.  
 
 
 
 
Figure 14: ROC curves of EPA values in patients with different pathologies. 
 
 
The greatest discriminating power of the test had occurred for the 
groups with cancer, cardiopathies and autoimmunity. A very high 
AUC value was found also for the patients in group 2c (“mixed” 
thyroid), probably due to interference of the other ongoing 
pathologies, especially dyslipidemia and hypertension.  
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The ROC curve areas (AUC) were not particularly significant for the 
other groups. 
 
 
 
 
Figure 15: ROC curves of DHA values in patients with different pathologies. 
 
 
In most groups the AUC of DHA was higher than 0.7. The results of 
the curves were highly significant in patients affected by cancer, 
cardiopathies and HCV. The highest accuracy was highlighted in the 
groups with allergies, autoimmunity and thyroid diseases. 
 
 
 
 
 
 
 
Results 
42 
 
 
 
 
Figure 16: ROC curves of DGLA values in patients with different pathologies. 
 
 
Since the ROC curve areas of DGLA were lower than 0.7 for almost 
all the groups, they were not particularly significant, except for groups 
of patients affected by allergy, autoimmunity and 
dyslipidemia/hypertension. 
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3.3.3 Mann Whitney U-test of PAR-PARP and fat profiles  
Since in most groups the number of analized cases was limited, the 
non parametric Mann Whitney U-test was applied to confirm the 
results of ROC curves. In Table 10 the comparison of results of both 
tests is reported. 
 
 
Table 10: ROC curve and Mann Whitney (MW) test of PAR-PARP and some 
ω3 and ω6 PUFAs of analysed groups.  
In the table ROC curve areas and them P values, and Mann Whitney test P values are 
reported. 
 
 
AUC: ROC areas that were maximally significant (AUC= 0.8-1) are highlighted in bold; 
those with P < 0.05 are in bold italics.   
MW test: only P values ≤ 0.1 are reported.   
 
 
Mann Whitney test generally confirmed the significance of the ROC 
curves in groups and subgroups with P value at least below 0.1. In 
some cases the significance was very high, with very low P values 
(0.01). On the other hand, in few cases the data of ROC area were 
different from MW P for same PUFAs, in particular for EPA in 
subgroup 2c, and DHA in subgroup 1c and group 6. 
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3.3.4 Correlation between AA levels versus EPA, DHA, DGLA  
The arachidonic acid (ω6) is the final product of the pro-inflammatory 
pathway. AA-derived eicosanoids have a role in regulating 
inflammatory mechanisms and their synthesis is influenced by the 
concentration of DGLA. As opposite EPA and DHA (ω3) are the 
products of the anti-inflammatory pathway. AA and EPA are formed 
by desaturases, specifically 5-desaturase, able to use both substrates 
(Figure 5). 
The intake of ω3 leads to synthesize EPA and DHA rather than AA. 
The correlation between AA and EPA, DHA, DGLA was evaluated in 
the different pathology groups with the Spearman’s correlation test. 
The results are reported in Table 11. 
 
 
Table 11: Spearman’s correlation test between AA versus EPA, DHA, DGLA. 
 
 
  Meaningful values (α = 0.05) are highlighted in bold. 
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The Spearman test indicated that the results of AA versus EPA were 
significant for subgroups 2b (Hashimoto’ thyroiditis) and 4a (HCV). 
In the former a direct correlation (= 1) was observed, whereas in the 
latter the correlation was inverse (= -1).  For AA versus DHA, in 
patients with mild thyroid disease (group 2a) and HCV (4a), AA was 
inversely correlated to DHA (= -1). As opposite, a direct correlation 
(= 1) was found in “mixed” thyroid diseases (group 2c) and “mixed” 
HCV (group 4b). However it was not possible to evaluate these results 
as both subgroups (group 2c, group 4b)  enclosed patients suffering of 
other diseases, someones (hypertension, dislipidemy, cancer, 
adenomas, polyposis, cardiopathy) with not significant.  
DGLA and AA were not associated in any pathology.  
It is worth noting that in subgroup 4a, both EPA and DHA inversely 
correlated with AA. 
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3.4 Correlation between PAR-PARP levels and PUFAs in the 
pathological groups 
The non parametric Spearman’s test was applied to evaluate a possible 
correlation between the levels of PAR-PARP and PUFAs in the 
pathology groups. The correlation coefficients were reported in Table 
12. 
 
 
       Table 12: Spearman’s correlation coefficient of PAR-PARP versus PUFAs. 
 
 
Meaningful values are highlighted in bold (±1). 
 
 
No association was found between the values of PARP and PUFAs for 
patients with gastroenteric diseases (groups 1, a-e), autoimmunity 
(group 5), no GE cancer (group 6) and dyslipidemia/hypertension 
(group 8).  
PAR-PARP versus EPA were directly related in patients with 
Hashimoto’s desease (group 2b), indirectly in those with HCV (group 
4a).  
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A direct correlation between PAR-PARP values and DHA was found 
in people with mild thyroid diseases and allergy, whereas the 
association was inverse in patients with HCV. 
As for PAR-PARP and DGLA a direct correlation was evidenced 
between the groups with “mixed” thyroid diseases and “mixed” HCV 
(groups 2c and 4b). 
In patients with Hashimoto’s disease (group 2b), HCV (group 4a) and 
cardiopathies (group 7), an increase of AA corresponded to very high 
levels of PAR-PARP. An inverse correlation was observed between 
AA and PAR-PARP in subjects with mild thyroid disease (group 2a). 
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4. Discussion/Conclusions 
 
This study started from both the knowledge that automodified PARPs 
(PAR-PARP), known as DNA break markers, are a direct measure of 
DNA damage extent, and that cell membrane lipid composition can be 
easily and accurately determined by fat profile. The research was 
carried on to study whether the tandem combination of the two tests 
could provide a non invasive tool to be used in the laboratory routine 
and able to depict the physio-pathological state of the cell.  
At present, this work is the first study that analyse, in tandem, at 
molecular level, two very important features of the cell, i.e. the 
integrity of DNA (through PAR-PARP levels) and the cell membrane 
status (fat profile), defining their statistical significance.  
Since diet is one of the most studied environmental factors in 
epigenetic changes (Waterland & Jirtle, 2003), there are increasing 
evidence that a correct quality of food intake and post-translational 
modification reactions (here namely poly(ADP-ribosyl)ation) might 
modulate deleterious processes as membrane lipid peroxidation and 
DNA damage respectively. 
The central role of PARP1 and 2 as DNA damage sensors is to 
contribute repairing nucleic acid damage (Yelamos et al., 2011). Both 
enzymes can be activated and automodified in response to DNA 
breaks by various patho-physiological conditions, including oxidative 
stress and inflammatory injury. Therefore, it is conceivable that their 
activity levels/expression in the cell nucleus can help in defining the 
physio-pathological state of the cell, offering a number of 
opportunities for therapeutic intervention in both cancer and other 
disease states (Morales et al., 2014). Moreover, key roles for PARPs 
in metabolic stress and homeostasis have been proposed (Bai & 
Cantó, 2012). Insufficient or excessive nutrients induce cells to 
rearrange their metabolism, energy stores/expenditure. Such 
rearrangements heavily impact inflammation. Lifestyle and dietary 
changes may affect modulation of PARP function to improve health 
(Bai & Cantó, 2012). For instance, the NAD
+
-consuming process is a 
consequence of PARP1 hyperactivation (Luo & Kraus, 2012; Kim et 
al., 2014). The adaptation ability of cells towards metabolic stress 
drives the physiological or pathological states, as metabolic- or age-
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related diseases (obesity, diabetes, cancer) (Wellen & Thompson, 
2010).  
As it regards PAR-PARP levels, our study confirmed their general 
meaning as DNA damage markers. Even before performing other 
more complex diagnostic analyses, and in accordance with data from 
literature, DNA damage is easily detectable by PAR-PARP measures. 
The results of blood analyses clearly evidenced that in those patients 
with pathologies involving DNA damage, they were altered as a 
function of DNA break extent. Therefore the first conclusion is that as 
routine analysis, PAR-PARP measure could be predictive of possible 
diseases involving DNA breakage. Moreover, it is worth considering 
that, as stated above, increasing PARP automodification is strictly 
related to NAD
+
 consumption. This reaction subtracts the pyridinic 
substrate from its coenzymatic function, and highly lowers its 
involvement in energy metabolism with deleterious consequences for 
ATP synthesis (Ying, 2006; Verdin, 2014). A relationship between 
PARP, DNA breakage, and niacin deficiency was reported previously 
(Pacher & Szabó, 2008). High PAR-PARP is an index of high 
consumption of NAD
+
 and allows to evaluate a possible need of niacin 
supplementation. PAR-PARP levels were independent from BMI 
values. They showed to correlate with occurrence of diseases. 
Namely, the healthy subjects of the 84 examined people had low 
PAR-PARP levels indicating a physiological DNA damage that occurs 
during normal metabolic events such as DNA replication, 
transcription, etc. In case of diagnosis of serious diseases, high levels 
of PAR-PARP were confirmed. These results highlight the above 
mentioned role of PARP automodification that is used widely as DNA 
damage biomarker, for instance in the diagnosis of infiltrating 
inflammatory cells during stroke, myocardial and reperfusion injury, 
myocardial hypertrophy and heart failure, cardiomyopathies, 
circulatory shock, cardiovascular aging, atherosclerosis and vascular 
remodeling after injury, diabetic complications, and 
neurodegenerative disorders, since there is a wide literature about 
involvement of PARP in all these pathologies (Geraets et al., 2007; 
Pacher & Szabó, 2007, 2008).  
 
On the other hand, lipidomic profiling is an important tool to 
explore the impact of nutrition and metabolism (Chatgilialoglu & 
Ferreri, 2012). Lipids are derived preformed directly from the diet or 
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by de novo synthesis from simple precursors. Variations in lifestyle 
and genetics influence the enzymatic activities involved in their 
metabolism. Dysregulation of lipid metabolism results in diseases. 
Moreover, cell membrane is a sensor that changes and adapts 
continuously to metabolic stimuli and to the external environment 
(diet, stress, physical and chemical agents), and its properties are  
regulated by fatty acid composition. 
The rationale of BMI analysis (first approach) arose from the 
observation that overweight and obesity have recently reached vast 
proportions worldwide, representing one of the main historical 
metabolic risk factors. The onset of these conditions of excess weight 
has remarkable effects on health status with an increased risk of 
inflammatory and cardiovascular diseases and some cancers. In this 
context, the first evaluation criterion was the comparison of the results 
of the analyses with both anthropometric measures (body mass index) 
and any clinical state of subjects undergoing the survey. As a result, in 
this study, the content of all FA categories was altered in any BMI 
groups.  
The evidenced excess of SFA was independent from anthropometric 
data. Even most of normal weight people had high SFA levels. Indeed 
SFA excess was an index of increased membrane rigidity, with 
consequent possible altered permeability and functionality. Moreover, 
it might indicate alterations in any enzymatic step of FA metabolism 
requiring further attention. In fact, in some cases the increase of 
MUFA like palmitoleic and vaccenic acids suggests the activation of 
the metabolic conversion of SFA into MUFA, to balance their excess 
and to reduce possible metabolic and cardiovascular risks (Baritaki et 
al., 2007; Ferreri, 2009; Chatgilialoglu et al., 2014). The knowledge 
of the actual status of a subject allows defining a dietary regimen to 
equilibrate the membrane lipids and to support specific therapies. In 
synthesis, these results at least allow correcting the quality of food, 
limiting the intake of nutritional sources of SFA, in order to re-
establish the right content of these FA category.  
A high unbalance was measured for ω6/ω3 PUFA too. In some cases, 
there was a net increase of arachidonic acid, a precursor of many pro-
inflammatory compounds, compared to the expected normal ranges. 
Mostly a high reduction of ω3 PUFA was observed. Due to the anti-
inflammatory value of these FA, their deficiency indicated a low anti-
oxidant defense ability of cells, and a high risk of inflammation.  
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A behavior similar to that evidenced for PAR-PARP levels.  
Statistical analyses did not evidence any correlation between the two 
tests in BMI patient groups. 
As a conclusion of the results of the first approach, the two analyses 
give information about DNA damage involvement (PAR-PARP 
levels), and on the balance of membrane lipids.  
 
The results reported for the second approach (the two tests versus 
pathologies) gave indications coherent with the data described in 
literature.  
In Table 11 the results reveal an indirect correlation between DHA 
and AA in patients affected by thyroid diseases. It has been widely 
demonstrated that omega 3 FAs regulate the levels of the thyroxine 
hormone, T4 (Taraghijou et al., 2012). This thyroid hormone plays a 
role in several body functions, including growth and metabolism. 
High levels of DHA, probably due to a therapeutic treatment ongoing, 
balance the pro-inflammatory effects of AA, stayed at low 
concentrations. 
In patients with Hashimoto’s hypothyroidism low levels of AA 
correspond to a decrease of EPA. In fact, it is known that this 
condition is characterized by a reduction of the AA levels (Guerriero 
et al., 1999). Moreover, the alteration of thyroid hormone synthesis is 
explained by the decrease of EPA. 
In group 4a (HCV) an increase of arachidonic acid, the inflammatory 
mediator, corresponded to a decrease in the levels of EPA and DHA. 
It is known that the excess of AA promotes the synthesis of 
prostanoids of group 2 (PGD2, PGE2, PGF2, PGI2, TXA2), 
leukotrienes of series 4 and lipoxins that favor the inflammatory 
effects (Ferreri & Chatgilialoglu, 2012).  
Evidence in the literature suggests that PUFAs can have both positive 
and negative effects on the host antiviral response (Anderson & 
Fritsche, 2002). PUFAs have the ability to inhibit HCV RNA 
replication at physiologically relevant concentrations (Das, 2008). 
AA, EPA and DHA had the capacity to exert anti-HCV activities 
using an HCV subgenomic RNA replicon system, that is independent 
of their ability to suppress lipogenic gene expression (Kapadia & 
Chisari, 2005; Liu et al., 2010). The anti-HCV action of PUFAs is due 
to the formation of significant products of lipid peroxidation that 
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occurs only in cells where the viral replication is activated (Huang et 
al., 2007). 
In patients with chronic hepatitis C the results showed a decrease of 
EPA and DHA, important modulators of a host’s 
inflammatory/immune responses (Chapkin et al., 2009). This decrease 
is probably due to antiviral therapy ongoing. Indeed, it is known that 
patients undergoing IFN-a and ribavirin treatment have markedly 
higher AA and decreased EPA levels in peripheral blood mononuclear 
cells (Hino et al., 2006).  
 
In table 12 the patients affected by thyroid diseases (group 2a) had a 
physiological level of PAR-PARP, as shown in the ROC curve 
(AUC= 0.54). Low values of PAR-PARP were associated to increased 
DHA.  
DHA balances the inflammatory effects of AA, and promotes the 
production of protective substances, such as neuroprotectin, which 
prevents inflammation in the neuronal tissue (Ferreri & 
Chatgilialoglu, 2012). 
Hashimoto’s desease (group 2b) caused a hyperactivation of PARP 
(AUC= 1), directly related to the increase of AA and EPA. Therefore 
the inflammatory effects of AA are unbalanced from the increase 
EPA, probably caused by the current treatment. 
In patients with allergy an increase of PAR-PARP corresponded to a 
increase in the levels of DHA and DGLA (groups 3a and 3b). 
Different studies suggested the involvement of PARP1 in the 
pathogenesis of allergic airway inflammation, such as asthma 
and allergic rhinitis  (Ozaydin et al., 2014). 
The activation of PARP results in an up-regulation of pro-
inflammatory gene expression countered by the action of ω3 PUFAs, 
that decrease the production of inflammatory mediators (eicosanoids, 
cytokines, and reactive oxygen species) and the expression of 
adhesion molecules. EPA and DHA suppress PGD2, IL-13 and IL-4 
secretion as well as ROS generation most effectively (van den Elsen et 
al., 2013). In this case DGLA has an anti-inflammatory effect because 
inhibits phospholipase A2, blocking the synthesis of AA and other 
pro-inflammatory mediators and releases anti-inflammatory PGE1. 
In patients with HCV (group 4a) PAR-PARP levels were directly 
correlated to those of the AA, inversely to the values of EPA and 
DHA. Higher levels of AA compared to those of EPA and DHA lead 
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to an overproduction of the pro-inflammatory prostaglandins of the ω6 
series and cytokines.  
The results of Sperman’s test showed a direct correlation between 
PAR-PARP and AA levels (group 7). PARP1 activation plays a role in 
the pathogenesis of various cardiovascular and inflammatory diseases 
(Szabó, 2005). The potential role of PARP2 in cardiovascular system 
was determined too. PARP2 deletion protected cardiomyocytes from 
hypertrophy, which may be attributed to activation of the key member 
of sirtuins (SIRT) family, SIRT1 (Geng et al., 2013).  
The inflammatory condition promotes the activation of PARP and 
simultaneously causes an alteration of the ω6/ω3 ratio. Different 
evidence in literature confirm the excessive amounts of ω6 
polyunsaturated fatty acids (PUFA) and a very high ω6/ω3 ratio the 
pathogenesis of many diseases, including cardiovascular disease, 
cancer, and inflammatory and autoimmune diseases (Simopoulos, 
2008).  
Recent findings suggest that higher plasma levels of ω6 PUFAs, 
mainly AA, were associated with decreased plasma levels of serum 
pro-inflammatory markers, particularly interleukin-6 and interleukin-1 
receptor antagonist, and increased levels of anti-inflammatory 
markers, particularly transforming growth factor-β. Therefore, AA and 
ω3 PUFAs may modulate the inflammatory response by acting both 
on the pro-inflammatory and anti-inflammatory arms of the cytokine 
network (Ferrucci et al., 2006; Harris et al., 2009). 
 
In conclusion, the two analyses in tandem seem to contribute to draw 
at least diagnostic clinical pictures to support therapeutic and/or 
nutraceutical approaches. 
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